...
adap-img

Adaptimmune Therapeutics Plc, Common Stock

ADAP

NSQ

$0.5914

+$0.01

(1.72%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$148.44M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
2.62M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
2.25
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.43 L
$2.05 H
$0.5914

About Adaptimmune Therapeutics Plc, Common Stock

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameADAPSectorS&P500
1-Week Return-5.54%-3.72%-0.05%
1-Month Return-0.61%-1.85%2.75%
3-Month Return-43.68%-11.4%7.4%
6-Month Return-36.88%-4.41%10.47%
1-Year Return31.57%4.13%27.57%
3-Year Return-83.62%0.3%29.56%
5-Year Return-55.53%36.62%89.3%
10-Year Return-96.3%106.81%206.09%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue1.12M3.96M6.15M27.15M60.28M[{"date":"2019-12-31","value":1.86,"profit":true},{"date":"2020-12-31","value":6.57,"profit":true},{"date":"2021-12-31","value":10.2,"profit":true},{"date":"2022-12-31","value":45.04,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue97.50M91.57M111.09M127.73M9.86M[{"date":"2019-12-31","value":76.34,"profit":true},{"date":"2020-12-31","value":71.69,"profit":true},{"date":"2021-12-31","value":86.98,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":7.72,"profit":true}]
Gross Profit(96.38M)(87.61M)(104.94M)(100.58M)50.42M[{"date":"2019-12-31","value":-191.14,"profit":false},{"date":"2020-12-31","value":-173.75,"profit":false},{"date":"2021-12-31","value":-208.12,"profit":false},{"date":"2022-12-31","value":-199.46,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin(8589.93%)(2213.49%)(1706.64%)(370.48%)83.65%[{"date":"2019-12-31","value":-10269.12,"profit":false},{"date":"2020-12-31","value":-2646.19,"profit":false},{"date":"2021-12-31","value":-2040.25,"profit":false},{"date":"2022-12-31","value":-442.9,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Operating Expenses140.89M137.36M168.40M191.11M200.02M[{"date":"2019-12-31","value":70.44,"profit":true},{"date":"2020-12-31","value":68.67,"profit":true},{"date":"2021-12-31","value":84.19,"profit":true},{"date":"2022-12-31","value":95.55,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(139.77M)(133.41M)(162.25M)(163.97M)(138.04M)[{"date":"2019-12-31","value":-13977000000,"profit":false},{"date":"2020-12-31","value":-13340500000,"profit":false},{"date":"2021-12-31","value":-16224600000,"profit":false},{"date":"2022-12-31","value":-16396500000,"profit":false},{"date":"2023-12-31","value":-13803800000,"profit":false}]
Total Non-Operating Income/Expense5.62M5.79M6.04M251.00K31.47M[{"date":"2019-12-31","value":17.86,"profit":true},{"date":"2020-12-31","value":18.39,"profit":true},{"date":"2021-12-31","value":19.2,"profit":true},{"date":"2022-12-31","value":0.8,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(136.92M)(129.93M)(157.30M)(162.96M)(112.53M)[{"date":"2019-12-31","value":-13692300000,"profit":false},{"date":"2020-12-31","value":-12993000000,"profit":false},{"date":"2021-12-31","value":-15729900000,"profit":false},{"date":"2022-12-31","value":-16295900000,"profit":false},{"date":"2023-12-31","value":-11253500000,"profit":false}]
Income Taxes242.00K162.00K791.00K2.50M1.34M[{"date":"2019-12-31","value":9.69,"profit":true},{"date":"2020-12-31","value":6.49,"profit":true},{"date":"2021-12-31","value":31.68,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":53.5,"profit":true}]
Income After Taxes(137.16M)(130.09M)(158.09M)(165.46M)(113.87M)[{"date":"2019-12-31","value":-13716500000,"profit":false},{"date":"2020-12-31","value":-13009200000,"profit":false},{"date":"2021-12-31","value":-15809000000,"profit":false},{"date":"2022-12-31","value":-16545600000,"profit":false},{"date":"2023-12-31","value":-11387100000,"profit":false}]
Income From Continuous Operations(137.16M)(130.09M)(158.09M)(165.46M)(113.87M)[{"date":"2019-12-31","value":-13716500000,"profit":false},{"date":"2020-12-31","value":-13009200000,"profit":false},{"date":"2021-12-31","value":-15809000000,"profit":false},{"date":"2022-12-31","value":-16545600000,"profit":false},{"date":"2023-12-31","value":-11387100000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(137.16M)(130.09M)(158.09M)(165.46M)(113.87M)[{"date":"2019-12-31","value":-13716500000,"profit":false},{"date":"2020-12-31","value":-13009200000,"profit":false},{"date":"2021-12-31","value":-15809000000,"profit":false},{"date":"2022-12-31","value":-16545600000,"profit":false},{"date":"2023-12-31","value":-11387100000,"profit":false}]
EPS (Diluted)(1.31)(0.96)(1.02)(1.00)(0.66)[{"date":"2019-12-31","value":-131,"profit":false},{"date":"2020-12-31","value":-96,"profit":false},{"date":"2021-12-31","value":-102,"profit":false},{"date":"2022-12-31","value":-100,"profit":false},{"date":"2023-12-31","value":-66,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ADAP
Cash Ratio 2.93
Current Ratio 3.85
Quick Ratio 3.82

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ADAP
ROA (LTM) -15.84%
ROE (LTM) -65.04%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ADAP
Debt Ratio Lower is generally better. Negative is bad. 0.75
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.25

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ADAP
Trailing PE NM
Forward PE NM
P/S (TTM) 1.05
P/B 1.86
Price/FCF NM
EV/R 0.21
EV/Ebitda NM
PEG 0.11

FAQs

What is Adaptimmune Therapeutics Plc share price today?

Adaptimmune Therapeutics Plc (ADAP) share price today is $0.5914

Can Indians buy Adaptimmune Therapeutics Plc shares?

Yes, Indians can buy shares of Adaptimmune Therapeutics Plc (ADAP) on Vested. To buy Adaptimmune Therapeutics Plc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ADAP stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Adaptimmune Therapeutics Plc be purchased?

Yes, you can purchase fractional shares of Adaptimmune Therapeutics Plc (ADAP) via the Vested app. You can start investing in Adaptimmune Therapeutics Plc (ADAP) with a minimum investment of $1.

How to invest in Adaptimmune Therapeutics Plc shares from India?

You can invest in shares of Adaptimmune Therapeutics Plc (ADAP) via Vested in three simple steps:

  • Click on Sign Up or Invest in ADAP stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Adaptimmune Therapeutics Plc shares
What is Adaptimmune Therapeutics Plc 52-week high and low stock price?

The 52-week high price of Adaptimmune Therapeutics Plc (ADAP) is $2.05. The 52-week low price of Adaptimmune Therapeutics Plc (ADAP) is $0.43.

What is Adaptimmune Therapeutics Plc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Adaptimmune Therapeutics Plc (ADAP) is

What is Adaptimmune Therapeutics Plc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Adaptimmune Therapeutics Plc (ADAP) is 1.86

What is Adaptimmune Therapeutics Plc dividend yield?

The dividend yield of Adaptimmune Therapeutics Plc (ADAP) is 0.00%

What is the Market Cap of Adaptimmune Therapeutics Plc?

The market capitalization of Adaptimmune Therapeutics Plc (ADAP) is $148.44M

What is Adaptimmune Therapeutics Plc’s stock symbol?

The stock symbol (or ticker) of Adaptimmune Therapeutics Plc is ADAP

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top